Eli Lilly and Company (BCBA:LLY)
Argentina · Delayed Price · Currency is ARS | Market Cap | 1,555.12T +56.2% |
| Revenue (ttm) | 118.03T +49.6% |
| Net Income | 39.57T +93.6% |
| EPS | 44,132.50 +94.8% |
| Shares Out | n/a |
| PE Ratio | 39.30 |
| Forward PE | 28.08 |
| Dividend | 107.46 (0.32%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 12,103 |
| Open | 33,780 |
| Previous Close | 33,540 |
| Day's Range | 32,880 - 33,960 |
| 52-Week Range | 17,720 - 36,520 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
Chinese drugmaker InnoCare Pharma said on Thursday it entered into a research collaboration and license agreement with Eli Lilly that could be worth up to about $3.35 billion.
Nektar shares pressured by jury notes in Lilly case, says B. Riley
B. Riley analyst Mayank Mamtani says jury deliberations are headed to the fourth day today in Nektar’s (NKTR) breach of contract trial against Eli Lilly (LLY). The jury’s notes review…
Nektar price target lowered to $50 from $80 at Wedbush
Wedbush lowered the firm’s price target on Nektar (NKTR) to $50 from $80 and keeps a Neutral rating on the shares. Following “speculation on failed litigation” against Eli Lilly (LLY),…
Nektar dropped as jury deliberates suit against Eli Lilly
Nektar (NKTR) shares dropped yesterday as a federal jury in San Francisco continued to deliberate the company’s breach of contract lawsuit against Eli Lilly (LLY) regarding Rezpeg. Nektar claims Lilly...
Ken Langone on Eli Lilly: Could be a $2,000 stock in the next 3-4 years
Ken Langone, Invemed Associates chairman and president and Home Depot co-founder, joins 'Squawk Box' to discuss the success of Home Depot, his thoughts on Eli Lilly, and more.
Pharmaceutical Companies Push Trump Administration to Protect China Deals
A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain Site will employ more than 600 people in high-wage jobs ...
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since Medicare coverage of obesity drugs launched in July. In an exclusive interview, Ricks said 70%...
Eli Lilly Stock (LLY) Rises After Company Provides Update on Obesity Pill Sales
The weight-loss medication launched in the U.S. this April.
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo
While being interviewed on CNBC, Eli Lilly (LLY) CEO Dave Ricks said one-third of new GLP-1 pill patients are taking the Foundayo pill and that the company is capturing 70%…
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly Stock (LLY) Rises as Novo’s Growth Strategy Fails to Impress Wall Street
Lilly controls 60% of the weight-loss drug market.
Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial
Shares in Danish obesity drugmaker Novo ($NVO) fell by 8% to around $40 on Monday morning, despite the company’s success in its late-stage Reimagine 5 trial. The study compared its…
Patients are suing GLP-1 drugmakers over the risk of sudden vision loss. The little-discussed potential risk of popular diabetes and weight-loss drugs is on warning labels outside of the U.S.
Michelle Fennell was sitting at her desk when her right eye started feeling heavy. Suddenly, it was blurry and her peripheral vision waned. It felt like she was looking through a fishbowl, she could s...
US FDA approves Lilly's breast cancer drug combo
The US FDA has approved Eli Lilly's drug combination to treat adults with a type of advanced breast cancer that has spread to other parts of the body, the drugmaker said on Friday.
Eli Lilly reports full FDA approval of Inluriyo combo for certain breast cancers
Eli Lilly (LLY) announced that the U.S. Food and Drug Administration has granted full approval to Inluriyo, an oral estrogen receptor antagonist, in combination with Verzenio, a CDK4/6 inhibitor, for…
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase ...
40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"
Raul Shah (@Raul_DSF) is very bullish on the future of GLP-1s due to accelerating demand trends generating a "mania" effect in the market. He points to the superiority Eli Lilly (LLY) has demonstrated...
Eli Lilly price target raised to $1,284 from $1,273 at Guggenheim
Guggenheim analyst Seamus Fernandez raised the firm’s price target on Eli Lilly (LLY) to $1,284 from $1,273 and keeps a Buy rating on the shares. The firm is updating its…
Twist Bioscience enters agreement with Lilly TuneLab
Twist Bioscience Corporation (TWST) announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (LLY). Twist is a provider of antibody cha...
3 Healthcare Stocks with More Than 20% Upside and Recent Buy Ratings
Eli Lilly ($LLY), UnitedHealth Group ($UNH), and Intuitive Surgical ($ISRG) have each received Buy ratings from Wall Street analysts on September 14. Based on their average analyst price targets, the…
Tuesday's First Moves: LLY & ETSY Upgrades, PLAY Plunges After Earnings
More and more, Eli Lilly (LLY) is being seen as the winner in the GLP-1 race over Novo (NVO), with Berenberg backing that thesis in its upgrade on the stock. Diane King Hall explains what the analyst ...
Options Corner: LLY Upgrade Injects Bullish Stock Momentum
Berenberg upgraded Eli Lilly (LLY) to buy from hold and boosted its price target to $1,400 from $1,220 as the healthcare giant extends its lead over Novo (NVO). Rick Ducat stacks the stock against its...
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes Findings fr...